Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity, potent activity, and relatively low toxicity. These attributes make peptides highly attractive for targeting complex diseases, including cancer, metabolic disorders, and autoimmune conditions. As the demand for innovative peptide drugs continues to grow, the need …Read More >

Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those with deficiencies in DNA repair mechanisms. However, the clinical efficacy of PARPi is often limited by the development of resistance, which poses a significant challenge to their long-term use. Elucidating the molecular mechanisms underlying PARPi …Read More >

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a key mediator of non-canonical Wnt signaling and plays a critical role in cancer progression. ROR1 is selectively and highly expressed in various solid tumors and hematological malignancies, while absent in normal adult tissue, making it a promising target for cancer therapy. Currently, there is a need …Read More >

Natural killer (NK) cells play a crucial role in the immune system and can recognize and kill cancer cells. Research in this area is focused on strategies for enhancing NK cell activity in tumor immunotherapy. These strategies include using monoclonal and multi-specific antibodies, as well as immune modulator molecules like cytokines, to redirect and stimulate …Read More >

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where cytotoxic payloads released by antibodies diffuse and kill nearby tumor cells, is a crucial mechanism, particularly in heterogeneous tumors where not all cells express the target antigen. This effect can enhance ADC efficacy, especially when …Read More >

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV virus, particularly through vaccines, is a promising approach for treating HPV-related cancers. Vaccines can be designed to stimulate the immune system to target and eliminate HPV-infected cells, potentially preventing cancer progression or even treating established …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 Festival …Read More >

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the largest and longest-standing cancer research conferences in the world, will be held in Chicago. At this year’s AACR meeting, WuXi Biology has been selected to present several posters detailing latest scientific insights, covering a range …Read More >

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present multiple posters detailing latest scientific insights, covering a range of cutting-edge topics from preclinical tumor model development and biomarker discovery, to the evaluation of novel anti-cancer therapies. Explore this quick overview of WuXi Biology’s pioneering …Read More >